Search Result

Results for "

Sglt2+Inhibitors

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Adenosine Receptor (1) Dipeptidyl Peptidase (2) GLP Receptor (1) HBV (1) Isotope-Labeled Compounds (9) Reactive Oxygen Species (ROS) (1) Reference Standards (10) SGLT (59)
By Research Areas:	Cancer (16) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (60) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-15409

Empagliflozin Maximum Cited Publications 89 Publications Verification BI 10773	SGLT	Infection Metabolic Disease Cancer
Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-10450

Dapagliflozin 65+ Cited Publications BMS-512148	SGLT	Metabolic Disease Cancer
Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury ^[2].

HY-10451

Canagliflozin 45+ Cited Publications JNJ 28431754	SGLT	Metabolic Disease Cancer
Canagliflozin (JNJ 28431754) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-10449

Luseogliflozin TS 071	SGLT	Metabolic Disease
Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC₅₀ of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC₅₀, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes ^[2].

HY-14894

Ipragliflozin 5+ Cited Publications ASP1941	SGLT	Metabolic Disease
Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-10450A

Dapagliflozin ((2S)-1,2-propanediol, hydrate) 65+ Cited Publications BMS-512148 (2S)-1,2-propanediol, hydrate	SGLT	Metabolic Disease Cancer
Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury ^[2].

HY-123011

Henagliflozin SHR3824	SGLT	Metabolic Disease
Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC₅₀ values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research .

HY-109144

Enavogliflozin DWP-16001	SGLT	Metabolic Disease
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor ^[2] .

HY-I0383

Canagliflozin hemihydrate 45+ Cited Publications JNJ 28431754 hemihydrate	SGLT	Metabolic Disease Cancer
Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-N2189

Swertisin 2 Publications Verification	Adenosine Receptor HBV SGLT	Infection Neurological Disease Inflammation/Immunology
Swertisin is an oral adenosine A1 receptor antagonist and an *SGLT2* inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice ^[2] .

HY-14945

Remogliflozin etabonate GSK189075	SGLT	Metabolic Disease
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .

HY-14894A

Ipragliflozin L-Proline 5+ Cited Publications	SGLT	Metabolic Disease
Ipragliflozin (L-Proline) is a highly potent and selective *SGLT2* inhibitor with an IC₅₀ of 2.8 nM; little and NO potency for SGLT1/3/4/5/6.

HY-15409R

Empagliflozin (Standard) BI 10773 (Standard)	Reference Standards SGLT	Metabolic Disease
Empagliflozin (Standard) is the analytical standard of Empagliflozin. This product is intended for research and analytical applications. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-13413

Tofogliflozin hydrate 4 Publications Verification CSG-452 hydrate	SGLT Reactive Oxygen Species (ROS)	Metabolic Disease
Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific sodium/glucose cotransporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.9 nM and K_i values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse *SGLT2* . Tofogliflozin partially inhibits high glucose-induced reactive oxyen species (ROS) generation in tubular cells ^[2].

HY-10450S

Dapagliflozin-d5 BMS-512148-d₅	Isotope-Labeled Compounds SGLT	Metabolic Disease Cancer
Dapagliflozin-d₅ is a deuterium labeled Dapagliflozin (HY-10450). Dapagliflozin is a competitive SGLT2 inhibitor .

HY-10451S

Canagliflozin-d4 JNJ 28431754-d₄	SGLT	Metabolic Disease Cancer
Canagliflozin-d₄ (JNJ 28431754-d₄) is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor .

HY-15409S

Empagliflozin-d4 BI 10773-d₄	SGLT	Metabolic Disease
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-109018

Velagliflozin 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

HY-14902

Tofogliflozin 4 Publications Verification CSG452	SGLT	Metabolic Disease
Tofogliflozin(CSG-452) is a potent and highly specific sodium/glucose cotransporter 2(SGLT2) inhibitor with Ki values of 2.9, 14.9, and 6.4 nM for human, rat, and mouse SGLT2.

HY-12608

TA-1887 JNJ-39933673	SGLT	Metabolic Disease
TA-1887 (JNJ-39933673) is a highly potent, selective and orally active *SGLT2* inhibitor (IC₅₀: 1.4 nM) with antihyperglycemic effects. TA-1887 can be used in the research of diabetes ^[2].

HY-10450R

Dapagliflozin (Standard) BMS-512148 (Standard)	Reference Standards SGLT	Metabolic Disease Cancer
Dapagliflozin (Standard) is the analytical standard of Dapagliflozin. This product is intended for research and analytical applications. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury ^[2].

HY-101122

LX2761	SGLT GLP Receptor	Metabolic Disease
LX2761 is an orally active, dual *SGLT1/SGLT2* inhibitor with IC₅₀ values of 2.2 nM and 2.7 nM against human *SGLT1* and *SGLT2, respectively. LX2761 locks human SGLT1 in an outward-open conformation and blocks its putative water permeation pathway. After oral administration, LX2761 is confined exclusively to the intestinal lumen, delays intestinal glucose absorption, regulates intestinal glucose metabolism, increases cecal glucose levels, reduces cecal pH, improves glycemic control and elevates plasma total GLP-1* levels. However, LX2761 induces diarrhea in a dose-dependent manner. LX2761 can be used in diabetes-related research ^[2] .

HY-109092

Licogliflozin 1 Publications Verification LIK066	SGLT	Metabolic Disease Inflammation/Immunology
Licogliflozin is a sodium glucose cotransporter (SGLT1 and *SGLT2*) inhibitor.

HY-10449A

Luseogliflozin hydrate TS 071 hydrate	SGLT	Metabolic Disease
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC₅₀ of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) ^[2].

HY-116223

Tianagliflozin	SGLT	Metabolic Disease
Tianagliflozin is a sodium/glucose cotransporter 2 (SGLT-2) inhibitor with potential for investigation in type 2 diabetes .

HY-122613

YM543 free base	SGLT	Metabolic Disease
YM543 free base is a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes ^[2].

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-12611

Sergliflozin etabonate GW-869682X	SGLT	Metabolic Disease
Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .

HY-Z0437

Dapagliflozin methyl acetate	SGLT	Metabolic Disease
Dapagliflozin methyl acetate is an orally active *SGLT2* inhibitor. Dapagliflozin methyl acetate may be used in type 2 diabetes research .

HY-138944

SGLT1/2-IN-1	SGLT	Metabolic Disease
SGLT1/2-IN-1 is a dual SGLT1/SGLT2 inhibitor extract from WO2015032272A1, compound 2 .

HY-10451R

Canagliflozin (Standard) JNJ 28431754 (Standard)	Reference Standards SGLT	Metabolic Disease Cancer
Canagliflozin (Standard) is the analytical standard of Canagliflozin. This product is intended for research and analytical applications. Canagliflozin (JNJ 28431754) is a selective *SGLT2* inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .

HY-117075

BI-44847	SGLT	Metabolic Disease
BI-44847 is a selective and orally active *SGLT2* inhibitor. BI-44847 can increase UGE and decrease HbA1c levels. BI-44847 shows improvement in fasting and fed glucose levels. BI-44847 can be studied in research on type 2 diabetes mellitus (T2DM) .

HY-14810

Atigliflozin AVE-2268	SGLT	Metabolic Disease
Atigliflozin (AVE-2268) is an orally active and selective *SGLT-2* inhibitor, with IC₅₀s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .

HY-101782

HSK0935	SGLT	Metabolic Disease
HSK0935 is a potent, highly selective and orally available *SGLT2* inhibitor with an IC₅₀ of 1.3 nM. Antihyperglycemic activities .

HY-109092A

rel-Licogliflozin rel-LIK066	SGLT	Metabolic Disease Inflammation/Immunology
rel-Licogliflozin is a relative configuration of Licogliflozin (HY-109092). Licogliflozin is a sodium glucose cotransporter (SGLT1 and *SGLT2*) inhibitor .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-122473

fluoro-Dapagliflozin	SGLT	Metabolic Disease
fluoro-Dapagliflozin, a structural analog of Dapagliflozin, is a selective *SGLT2* inhibitor with K_i values of 5.3 nM and 330 nM for SGLT2 and SGLT1, respectively. fluoro-Dapagliflozin blocks glucose transport and glucose-coupled currents .

HY-10451S2

Canagliflozin-d6 JNJ 28431754-d₆	SGLT	Metabolic Disease
Canagliflozin-d₆ is the deuterium labeled Canagliflozin . Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively ^[2].

HY-15409S1

Empagliflozin-13C6 BI 10773-¹³C₆	Isotope-Labeled Compounds	Metabolic Disease Cancer
Empagliflozin- ¹³C₆ (BI 10773- ¹³C₆) is ¹³C labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-15409S2

Empagliflozin-d6 BI 10773-d₆	Isotope-Labeled Compounds SGLT	Metabolic Disease Cancer
Empagliflozin-d₆ (BI 10773-d₆) is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-178167

SGLT2-IN-3	SGLT	Metabolic Disease
SGLT2-IN-3 is a sodium-glucose co-transporter 2 (SGLT2) inhibitor. SGLT2-IN-3 can inhibit glucose uptake. SGLT2-IN-3 can be used for the research of metabolic disease, such as diabetes .

HY-10450S5

Dapagliflozin-13C6-1	Isotope-Labeled Compounds SGLT	Metabolic Disease Cancer
Dapagliflozin- ¹³C₆-1 is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury ^[2].

HY-10450S3

Dapagliflozin-13C6 BMS-512148-¹³C₆	Isotope-Labeled Compounds	Metabolic Disease Cancer
Dapagliflozin- ¹³C₆ (BMS-512148- ¹³C₆) is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury ^[2].

HY-114598

WAY-123783	SGLT	Metabolic Disease
WAY-123783 is a potent, selective and orally active sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor producing activity after metabolism. WAY-123783 can increase the excretion of sugar in urine and at the same time lower the blood sugar level in db/db mice (ED₅₀ = 9.85 mg/kg). WAY-123783 can be used for the research of metabolic disease, such as diabetes ^[2].

HY-14894R

Ipragliflozin (Standard) ASP1941 (Standard)	Reference Standards SGLT	Metabolic Disease
Ipragliflozin (Standard) is the analytical standard of Ipragliflozin. This product is intended for research and analytical applications. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent .

HY-10450S2

Dapagliflozin-d4 BMS-512148-d₄	Isotope-Labeled Compounds SGLT	Metabolic Disease Cancer
Dapagliflozin-d₄ (BMS-512148-d₄) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury ^[2].

HY-14894S2

Pragliflozin-13C6 ASP1941-¹³C₆	Isotope-Labeled Compounds SGLT	Metabolic Disease
Pragliflozin- ¹³C₆ (ASP1941- ¹³C₆) is ¹³C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent ^[2].

HY-125327

YM-543	SGLT	Metabolic Disease
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.

HY-10450AR

Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) BMS-512148 (2S)-1,2-propanediol, hydrate (Standard)	Reference Standards SGLT	Metabolic Disease Cancer
Dapagliflozin ((2S)-1,2-propanediol, hydrate) (Standard) is the analytical standard of Dapagliflozin ((2S)-1,2-propanediol, hydrate). This product is intended for research and analytical applications. Dapagliflozin ((2S)-1,2-propanediol, hydrate) is the S-enantiomer of Dapagliflozin 1,2-propanediol, hydrate. Dapagliflozin ((2S)-1,2-propanediol, hydrate), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin ((2S)-1,2-propanediol, hydrate) induces HIF1 expression and attenuates renal IR injury ^[2].

HY-109018R

Velagliflozin (Standard)	Reference Standards SGLT	Metabolic Disease
Velagliflozin (Standard) is the analytical standard of Velagliflozin (HY-109018). This product is intended for research and analytical applications. Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2189

Swertisin 2 Publications Verification	Iridaceae Classification of Application Fields Flavones Metabolic Disease Plants Iris tectorum Maxim. Flavonoids other families Phenols Polyphenols Inflammation/Immunology Disease Research Fields Source Classification	Adenosine Receptor HBV SGLT
Swertisin is an oral adenosine A1 receptor antagonist and an *SGLT2* inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice ^[2] .

Cat. No.	Product Name	Chemical Structure

HY-10450S

Dapagliflozin-d5
Dapagliflozin-d₅ is a deuterium labeled Dapagliflozin (HY-10450). Dapagliflozin is a competitive SGLT2 inhibitor .

HY-10451S

Canagliflozin-d4
Canagliflozin-d₄ (JNJ 28431754-d₄) is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor .

HY-15409S

Empagliflozin-d4
Empagliflozin-d₄ is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-10451S2

Canagliflozin-d6
Canagliflozin-d₆ is the deuterium labeled Canagliflozin . Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC₅₀s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively ^[2].

HY-15409S1

Empagliflozin-13C6
Empagliflozin- ¹³C₆ (BI 10773- ¹³C₆) is ¹³C labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-15409S2

Empagliflozin-d6
Empagliflozin-d₆ (BI 10773-d₆) is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-10450S5

Dapagliflozin-13C6-1
Dapagliflozin- ¹³C₆-1 is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury ^[2].

HY-10450S3

Dapagliflozin-13C6
Dapagliflozin- ¹³C₆ (BMS-512148- ¹³C₆) is ¹³C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury ^[2].

HY-10450S2

Dapagliflozin-d4
Dapagliflozin-d₄ (BMS-512148-d₄) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine . Dapagliflozin induces HIF1 expression and attenuates renal IR injury ^[2].

HY-14894S2

Pragliflozin-13C6
Pragliflozin- ¹³C₆ (ASP1941- ¹³C₆) is ¹³C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective *SGLT2* inhibitor with IC₅₀s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent ^[2].

HY-166652S

Empagliflozin-d8
Empagliflozin-d₈ is the deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC₅₀ of 3.1 nM for human SGLT-2 .

HY-166548S

Remogliflozin etabonate-d7

Remogliflozin etabonate-d₇ (GSK189075-d₇) is the deuterium labeled Remogliflozin etabonate. Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with K_i values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Sglt2+Inhibitors

Inhibitors & Agonists

NaturalProducts

Isotope-Labeled Compounds

Natural
Products